Targeting individual pain catastrophizing to reduce migraine-related disability: a randomized controlled proof-of-concept trial using an online CBT intervention
Abstract
This mechanistic randomized controlled proof-of-concept trial (RCT) investigated whether a brief online Cognitive Behavioral Therapy (CBT)-based avatar intervention can reduce individual pain catastrophizing in individuals with migraine and examined whether reductions in individual pain catastrophizing are associated with decreased migraine-related disability. Migraine is a highly disabling disorder, yet the mechanisms underlying migraine-related disability remain poorly understood. The Fear Avoidance Model (FAM) and recent research suggest that pain catastrophizing is a key mediator linking migraine experience with disability. A total of N = 55 individuals with migraine and ≥ 4 migraine days/month were randomized to either an intervention group (receiving cognitive restructuring targeting individual pain catastrophizing statements), or an active control group (contradicting false statements about migraine). Assessments at baseline, post-intervention, and six-week follow-up included individual Pain Catastrophizing (PCS-3), Headache Impact Test (HIT-6), as well as migraine-related and clinical characteristics. Intervention was evaluated using linear mixed-effects model. Hierarchical regression was used to determine the predictive effect of reductions in pain catastrophizing on reductions in disability. The intervention group demonstrated significantly greater reductions in pain catastrophizing at post-intervention (p = 0.009), while group differences diminished by follow-up.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 55 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.